 JENA, Germany, Jan. 05, 2021 GLOBE NEWSWIRE -- InflaRx Nasdaq: IFRX, a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today the European phase II IXCHANGE study of vilobelimab IFX-1, a first-in-class anti-C5a antibody, in ANCA-associated vasculitis AAV has completed enrollment. 